
Scientific Program

OMICS Group Conferences
Accelerating Scientific Discovery

4th World Congress on
Bioavailability and Bioequivalence:
Pharmaceutical R&D Summit

May 20-22, 2013 DoubleTree by Hilton Beijing, China



Sponsors & Exhibitors

"Organize your Events at OMICS Group Conferences"

Proposals are invited for organizing Symposia/Workshops at OMICS Group Conferences or OMICS Group will sponsor small events at your universities in related areas under the title of your own. These proposals can be sent to respective conference mail ids or to *symposia@omicsonline.org*

OMICS Group Conferences
5716 Corsa Ave., Suite 110, Westlake Los Angeles, CA 91362-7354, USA
Phone: +1-650-268-9744, Fax: +1-650-618-1414, Toll free: +1-800-216-6499
Email: *babe2013@omicsonline.com*

Day 1 May 20, 2013

08:00-09:00 Registrations

Cedar Tree

OMICS Group Conferences
Accelerating Scientific Discovery

09:00-09:20 **Opening Ceremony**

Keynote Forum

09:20-09:25 **Dr. Su Chen Video Presetation**

09:25-09:30 Introduction

09:30-09:55 **Michael Retsky**
Harvard School of Public Health, USA

09:55-10:20 **Yibin Feng**
The University of Hong Kong, China

Coffee Break 10:20-10:35 @ Juniper Tree

10:35-11:00 **Shein-Chung Chow**
Duke University School of Medicine, USA

11:00-11:25 **Sinerik Ayrapetyan**
UNESCO, Armenia

Group Photo

Track 1: Current Issues on Bioavailability and Bioequivalence (BA/BE) Determination

Session Introduction

Chair: **Shein-Chung Chow**, Duke University School of Medicine, USA
Co-Chair: **Ping Ren**, CDER/FDA, USA

11:25-11:45 T_{max} **evaluation in the bioequivalence studies of generic modified release proton pump inhibitors**
Ping Ren, CDER/FDA, USA

11:45-12:05 **Wax-matrix extended-release niacin vs inositol hexanicotinate: A comparison of wax-matrix, extended-release niacin to inositol hexanicotinate "no-flush" niacin in persons with mild to moderate dyslipidemia**
Joseph M. Keenan, University of Minnesota, USA

12:05-12:25 **5-Cholesten-3,25-diol 3-sulfate decreases lipid accumulation in dietinduced nonalcoholic fatty liver disease mouse model**
Shunlin Ren, Virginia Commonwealth University, USA

12:25-12:45 **Enhancing API bioavailability via nanotechnology for drug delivery**
Shawn X. Yin, Bristol-Myers Squibb Company, USA

Lunch Break 12:45-13:30 @ Easy Kitchen

13:30-13:50 **Application of nanotechnology for targeting brain delivery**
Jiukuan Hao, University of Cincinnati, USA

13:50-14:10 ***In Vivo* and *In Vitro* bioequivalence testing-Recent development for generic approval in the United States**
Shein-Chung Chow, Duke University School of Medicine, USA

14:10-14:30 **Enhancement of the ocular bioavailability of Cyclosporine A by cationic polymeric nanoparticles**
Ebru Basaran, Anadolu University, Turkey

14:30-14:50 **Acarbose bioequivalence: Exploration of new pharmacodynamic parameters**
Jin Yang, China Pharmaceutical University, China

14:50-15:10 **Vitamin A modulates the expression of genes involved in iron bioavailability**
Marta Citelli, Universidade do Estado do Rio de Janeiro, Brazil

Coffee Break 15:10-15:25 @ Juniper Tree

15:25-15:45 **Use of healthy male volunteers in bioequivalence studies of antineoplastic drugs: A pivotal study with capecitabine**
Gilberto De Nucci, Galeno Research Unit, Brazil

15:45-16:05 **Bioequivalence study of Trimetazidine modified release tablet formulations in indonesian healthy subjects**
Yahdiana Harahap, University of Indonesia, Indonesia

16:05-16:25 **A bioequivalence study of two finofibrate tablet formulations in indian healthy subjects**
Gaikwad, Rashtra Sant Tukadoji Maharaj Nagpur University, India

16:25-16:45 **Fever as a predictive factor in the autism spectrum disorders**
Amalia S. F. Megremi, University of Athens, Greece

16:45-17:05 **Pharmaceutical absorption modeling - A novel approach for formulation development**
Z. Jane Li, Boehringer Ingelheim Pharmaceuticals, USA

Panel Discussion

17:05-18:05 Cocktails sponsored by **Journal of Bioequivalence & Bioavailability** **@Juniper Tree**

Day 2 May 21, 2013

Cedar Tree

Track 1-10: Bioavailability and bioequivalence: FDA approaches and regulations
Track 1-11: Bioequivalence study for cancer drugs

Session Introduction

Chair: **Sinerik Ayrapetyan,** UNESCO, Armenia
Co-Chair: **Michael Retsky,** Harvard School of Public Health, USA

10:00-10:20 **Bioavailability and bioequivalence studies for chinese medicines: Challenge and opportunity**
Yibin Feng, The University of Hong Kong, China

10:20-10:40 **Failure of cell-hydration controlling signaling system is a gate for medical disorders**
Sinerik Ayrapetyan, UNESCO, Armenia

Coffee Break 10:40-10:55 @ Juniper Tree

10:55-11:15 **Perioperative NSAIDs may reduce early relapses in breast cancer: Perhaps transient systemic inflammation after surgery leads to these relapses**
Michael Retsky, Harvard School of Public Health, USA

11:15-11:35 **Cancer and heart disease: Novel insights aimed at diagnosis and drug therapy**
John A. Loudon, Wetherill Park Medical Centre, Australia

11:35-11:55 **The evaluation of biosimilarity index based on reproducibility probability for assessing biosimilars**
Aijing Zhang, North Carolina State University, USA

Track 2: Drug Design, Discovery, and Development
Track 3: PK/PD Models, Biowaivers, and Biosimilars
Track 4: Oral Bioavailability Enhancement
Track 5: Pharmacokinetics and BA/BE

Session Introduction

Chair: **Guo Ruichen,** Shandong University, China
Co-Chair: **Yuan Chen,** Genentech, USA

11:55-12:15 **Protein domain analysis from genomic sequence data revealed the regulation of LRR related domains in plant transpiration in Ficus**
Tiange Lang, Chinese Academy of Sciences, China

12:15-12:35 **A new structure of porous silica to overcome drug solubility challenges**
H. Leonhard Ohrem, Merck Millipore, Germany

Lunch 12:35-13:35 @ Easy Kitchen

13:35-14:20 **Poster Presentations** **@Juniper Tree**

14:20-14:40 **Consistency evaluation of the nifedipine oral formulations**
Guo Ruichen, Shandong University, China

14:40-15:00 **TDI - DDI risk assessment from *In Vitro* to *In Vivo* – Application of pbpk modeling and simulation tool**
Yuan Chen, Genentech, USA

15:00-15:20 **Co-treatment with selenium and zinc: A probable therapy against cadmium toxicity**
Jihen El Heni, Faculty of Medicine of Monastir, Tunisia

15:20-15:40 **Neuroprotective and antioxidant potential of indian traditional herb *Cynodon Dactylon***
S. Palani, Arunai Engineering College, India

15:40-16:00 **Biopharmaceutical and biosimilar products in brazil: From political to biotechnological overview**
Patricia Pelegrini, Embrapa, Brazil

Coffee Break 16:00-16:15 @ Juniper Tree

16:15-16:35 **Nitric oxide can convert into nitrogen in blood**
Tao Li, China Three Gorges University, China

16:35-16:55 **A new pharmacokinetic study model using simultaneous automated drug infusion/blood sampling system in freely moving rats**
Bijay Aryal, Chitwan Medical College P.Ltd, Nepal

16:55-17:15 **Comparative bioequivalence, safety and performance evaluation of novel matrix type oxybutynin transdermal patch**
Achyut Khire, Institute of Chemical Technology, India

17:15-17:35 **Challenges and regulatory implications of CRO industry to meet global quality standards**
Ravi Kanneti, Dr. Reddys Laboratories Ltd., India

17:35-17:55 **Study on sodium benzoate by chiral ligand exchange capillary electrophoresis based on its inhibitory activity in D-amino acid oxidase mediated oxidation of D-serine**
Li Qi, Chinese Academy of Sciences, P. R. China

17:55-18:15 **Disposition of Ceftriaxone following single intravenous, intramuscular and intramammary administration with special reference to its metabolism in small ruminant model**
Tapas Kumar Sar, West Bengal University of Animal & Fishery Sciences, India

18:15-19:15 Cocktails sponsored by **Journal of Bioanalysis & Biomedicine** **@Juniper Tree**

Day 3 May 22, 2013

Cedar Tree

Track 6: BA/BE of Novel Drug Delivery Systems
Track 7: Strategies and Challenges in Bioanalysis
Track 8: Bioavailability of Pharmaceuticals, Nutrients, and Other Supplements

Session Introduction

Chair: **Hu Yan**, Zhengzhou University, China
Co-Chair: **Peisheng Xu**, University of South Carolina, USA

09:30-09:50 **Multicompartment intracellular self-expanding nanogel for targeted delivery of drug cocktail**
Peisheng Xu, University of South Carolina, USA

09:50-10:10 **Human monoclonal anti-EGFR antibodies for cancer therapeutic**
Yu Zhou, UCSF and Comprehensive Cancer Center, USA

10:10-10:30 **Targeting beta-catenin signaling in gugulipid-induced apoptosis in human breast cancer cells by gugulipid extract of ayurvedic medicine plant *Commiphora mukul***
Dong Xiao, University of Pittsburgh, USA

10:30-10:50 ***In Vitro* susceptibility to antimonials and Amphotericin B of Leishmania infantum strains isolated from dogs in a region lacking drug selection pressure**
Khatima AIT-OUDHIA, National Higher School of Veterinary, Algeria

Coffee Break 10:50-11:05 @ Juniper Tree

11:05-11:25 **A comparative BA/BE study of conventional and sustained-release tablet formulations of aceclofenac in healthy male subjects**
B. B. Barik, Jazan University, Kingdom of Saudi Arabia

11:25-11:45 **Bioavailability for lower respiratory tract infection drugs among neonatal and adults population in Kilimanjaro, Tanzania**
Bernard Mbwele, Kilimanjaro Clinical Research Institute, Tanzania

11:45-12:05 **Single-walled-carbon-nanotube-based field-effect transistors with biosensing functions for prostate-specific-antigen**
Hu Yan, Zhengzhou University, China

Track 10: BA/BE Policies and Requirements
Track 11: Bioavailability, Bioequivalence, and Drug Product Selection

Session Introduction

Chair: **Shengjun Zhang**, Frontage China Clinical Services, China
Co-Chair: **Xin Xu**, National Center for Advancing Translational Sciences, USA

12:05-12:25 **Effects of CYP3A5 and CYP2D6 genetic polymorphism on the pharmacokinetics of diltiazem and its metabolites in Chinese subjects**
Shengjun Zhang, Frontage China Clinical Services, China

12:25-12:45 **Bioavailability assessment for subcutaneously administered biologics in animal models**
Xin Xu, National Center for Advancing Translational Sciences, USA

Lunch 12:45-13:45 @ Easy Kitchen

13:45-14:05 **Novel exploratory approaches to define clinical Absolute Bioavailability and other ADME properties**
Graeme Young, GlaxoSmithKline Research and Development Ltd., UK

14:05-14:25 **Antihypertensive drug development based on direct effects of statins on vascular smooth muscle**
Xi-Long Zheng, The University of Calgary, Canada

14:25-14:45 **The evaluation of NGF/BDNF sustained release system designed for nerve regeneration**
Fenghua Xu, PLA General Hospital, China

14:45-15:05 **Bioavaliability of tylosin tartrate after flock medication via drinking water in broilers**
Aqeel, University of Veterinary and Animal Sciences, Pakistan

Award Ceremony

Bookmark your dates

OMICS Group Conferences
Accelerating Scientific Discovery

5th World Congress on
Bioavailability and Bioequivalence:
Pharmaceutical R&D Summit
May 2014 USA

OMICS Group Inc.
2360 Corporate Circle, Suite 400
Henderson, NV 89074-7722, USA
Ph: +1-888-843-8169
Fax: +1-650-618-1417
omicsonline@omicsonline.com

OMICS Publishing Group
5716 Corsa Ave., Suite 110, Westlake
Los Angeles, CA 91362-7354, USA
Ph: +1-650-268-9744
Fax: +1-650-618-1414
omicsonline@omicsonline.org

OMICS Group
SEZ Unit, Building No. 20, 9th Floor
APIIC Layout, HITEC City
Hyderabad-500081, AP, INDIA
Ph: 040-40131823, 040-47482222
omicsgroup@omicsgroup.org

Toll free
USA & Canada: +1-800-216-6499
Australia: +1-800-651-097
Europe: 0805-080048